Positron Appoints Charles Conroy As Chief Operating Officer
CHICAGO, Nov. 15, 2012 /PRNewswire/ -- Positron Corporation (OTCBB:POSC), a nuclear medicine healthcare company, announced today the appointment of Charles Conroy as Chief Operating Officer.
Conroy's background includes extensive experience in corporate & product strategy, partner & alliance management, licensing, acquisitions, divestitures and portfolio management. During his career, Conroy has led highly successful global business development, marketing, and operations initiatives for companies including Covidien, Eli Lilly, and Amerinet. Conroy earned a Bachelor of Science in Pharmacy from Purdue University and a Master of Business Administration from the University of Michigan.
As COO, Conroy will define and implement strategies focused on accelerating growth across the company's product portfolio. Conroy joins Positron's clinical and technical executive team, consisting of: Joseph Oliverio (PET), Jason Kitten (Radiopharmaceutical/Radioisotope Production) and Scott Stiffler (Pharmaceutical Automation/Product Development). Conroy will also lead the Company's sales and marketing initiatives; focusing on revenue generation, enhancing Positron's industry position and brand recognition as a leader in nuclear medicine.
Conroy commented, "I am very excited to be joining the Positron team. As the only company with a full nuclear cardiology solution, Positron is well positioned to take a leadership role in the nuclear medicine industry. The caliber of the team and the company's reputation coupled with its strong sense of purpose make this a tremendous opportunity."
"Chuck's leadership, expertise and background of implementing an integrated global sales and marketing plan adds tremendous value in executing Positron's objectives," stated Patrick G. Rooney, Chief Executive Officer of Positron. "Chuck's approach and track record will greatly complement the knowledge and direction provided by each member of our executive team in executing our vertically integrated solution strategy. We are pleased with the addition of Chuck Conroy as our COO and I expect him to have a significant impact in all aspects of our business. We have developed a business model and team to deliver results."
About Positron: Positron Corporation is a nuclear medicine healthcare company vertically integrating all the segments of nuclear cardiology; providing an end-to-end solution for cardiac PET. Through proprietary PET imaging systems, radiopharmaceuticals and radioisotopes solutions, Positron enables healthcare providers to more accurately diagnose disease and improve patient outcomes, while practicing cost effective medicine. Positron's unique products, market position and approach in securing the supply chain are substantial advantages, further accelerating the adoption of cardiac PET and growth of nuclear cardiology. Positron is redefining the industry. More information about Positron is available at www.positron.com.
Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Positron assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.
SOURCE Positron Corporation